1073371-99-9

Usage

Uses

3-Hydroxy-4-methoxycarbonylphenylboronic acid, pinacol ester

Upstream product

• 18179-39-0 methyl 4-iodosalicylate 
• 73183-34-3 bis(pinacol)diborane 
• 22717-56-2 4-bromo-2-Hydroxybenzoic Acid Methylester 
• 149878-72-8 2-hydroxy-4-trifluoromethanesulfonyloxybenzoic acid methyl ester 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 89-86-1 4-hydroxysalicylic acid 

Downstream Products

• 1374263-36-1 methyl 4-[3-(4-{1-[(tert-butoxycarbonyl)amino]cyclobutyl}phenyl)-9H-imidazo[1,2-d]pyrido[2,3-b][1,4]benzodiazepin-2-yl]-2-hydroxybenzoate 
• 1429313-07-4 methyl 4-[5-(2,2,3,3,13,13-hexamethyl-11-oxo-4,7,12-trioxa-10-aza-3-silatetradecan-10-yl)pyrazolo[1,5-a]pyrimidin-3-yl]-2-hydroxybenzoate 
• 1429313-08-5 methyl 4-(5-{[(tert-butoxy)carbonyl][2-(2-hydroxyethoxy)ethyl]amino}pyrazolo[1,5-a]pyrimidin-3-yl)-2-hydroxybenzoate 
• 1429313-23-4 C₂₈H₃₇N₅O₈ 
• 1429313-22-3 C₃₄H₅₁N₅O₈Si 

Relevant academic research and scientific papers

Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor

Casein kinase 2 (CK2) is a constitutively expressed serine/threonine kinase that has a large diversity of cellular substrates. Thus, CK2 has been associated with a plethora of regulatory functions and dysregulation of CK2 has been linked to disease development in particular to cancer. The broad implications in disease pathology makes CK2 an attractive target. To date, the most advanced CK2 inhibitor is silmitasertib, which has been investigated in clinical trials for treatment of various cancers, albeit several off-targets for silmitasertib have been described. To ascertain the role of CK2 inhibition in cancer, other disease and normal physiology the development of a selective CK2 inhibitor would be highly desirable. In this study we explored the pyrazolo [1,5-a]pyrimidine hinge-binding moiety for the development of selective CK2 inhibitors. Optimization of this scaffold, which included macrocyclization, led to IC20 (31) a compound that displayed high in vitro potency for CK2 (KD = 12 nM) and exclusive selectivity for CK2. X-ray analysis revealed a canonical type-I binding mode for IC20 (31). However, the polar carboxylic acid moiety that is shared by many CK2 inhibitors including silmitasertib was required for potency but limits the cellular activity of IC20 (31) and the cellular IC50 dropped to the low micromolar range. In summary, IC20 (31) represents a highly selective and potent inhibitor of CK2, which can be used as a tool compound to study CK2 biology and potential new applications for the treatment of diseases.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS.

The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs comprising different metals or metal ions and/or a plurality of organic linking moieties comprising different functional groups.

HYDROXY FORMAMIDE DERIVATIVES AND THEIR USE

Disclosed are compounds having the formula (I): wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.

Synthesis, biological evaluation and modeling studies of terphenyl topoisomerase II α inhibitors as anticancer agents

We report the synthesis and evaluation of a series of novel terphenyls. Compound 17 had the most potent anticancer activity, indicating that the phenolic hydroxyl was a key group. A DNA relaxation test showed that compound 17 had a strong inhibitory effec

Metal-organic frameworks with precisely designed interior for carbon dioxide capture in the presence of water

The selective capture of carbon dioxide in the presence of water is an outstanding challenge. Here, we show that the interior of IRMOF-74-III can be covalently functionalized with primary amine (IRMOF-74-III-CH2NH 2) and used for the selective capture of CO2 in 65% relative humidity. This study encompasses the synthesis, structural characterization, gas adsorption, and CO2 capture properties of variously functionalized IRMOF-74-III compounds (IRMOF-74-III-CH3, -NH2, -CH2NHBoc, -CH2NMeBoc, -CH 2NH2, and -CH2NHMe). Cross-polarization magic angle spinning 13C NMR spectra showed that CO2 binds chemically to IRMOF-74-III-CH2NH2 and -CH2NHMe to make carbamic species. Carbon dioxide isotherms and breakthrough experiments show that IRMOF-74-III-CH2NH2 is especially efficient at taking up CO2 (3.2 mmol of CO2 per gram at 800 Torr) and, more significantly, removing CO2 from wet nitrogen gas streams with breakthrough time of 610 ± 10 s g-1 and full preservation of the IRMOF structure.

MACROCYCLIC FLT3 KINASE INHIBITORS

The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

MACROCYCLIC FLT3 KINASE INHIBITORS

The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.